Bivision Pharmaceuticals

Bivision Pharmaceuticals is a biopharmaceutical company focused on the development of targeted radionuclide therapy (TRT) with integrated visualization diagnostics and therapeutics. It strives to become a leader in China’s TRT field through innovation and collaboration, benefiting cancer patients and those with other severe diseases worldwide. Bivision Pharmaceuticals possesses three major technological platforms: targeted ligand screening, radiopharmaceutical conjugation, and clinical drug translation, with multiple R&D pipelines advancing simultaneously. The company’s four co-founders have led innovative drug development at multinational pharmaceutical companies such as Eli Lilly, Roche, GlaxoSmithKline, and Siemens, accumulating over 60 years of experience collectively, nearly half of which has been in the TRT field. Their achievements include 4 NDAs and 15 INDs.